Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma (RPRX) announced a significant adjustment to its 2023 financial guidance, now expecting Adjusted Cash Receipts between $2,850 million and $2,950 million, up from previous estimates of $2,375 million to $2,475 million. This change follows a $475 million milestone payment from Pfizer after the FDA approved Zavzpret, a new migraine treatment. Royalty Pharma will collect royalties from both Zavzpret and Nurtec ODT sales. The guidance assumes no unforeseen adverse events and may be adjusted for new royalty transactions.
Royalty Pharma (Nasdaq: RPRX) has appointed Ashwin Pai, M.D., as Executive Vice President, Investments effective April 2023. He joins from Morgan Stanley, bringing nearly two decades of experience in biotechnology investment banking, having led major mergers and acquisitions. Ashwin's role will focus on sourcing and executing transactions, enhancing Royalty Pharma’s position within the life sciences sector, particularly on the West Coast. The firm, established in 1996, is a leading funder of biopharmaceutical innovation, holding royalties on over 35 commercial products, including therapies from Vertex and Biogen.
Royalty Pharma (Nasdaq: RPRX) reported Q4 and full year 2022 results showcasing strong financial performance. Net cash from operating activities reached $570 million, reflecting a 16% increase for the quarter and 6% for the year. Adjusted Cash Receipts surged 96% to $1,064 million in Q4 and 31% to $2,789 million for the year, driven by a $458 million payment from Pfizer’s Biohaven acquisition. For 2023, the company expects Adjusted Cash Receipts between $2,375 million and $2,475 million, excluding potential milestone payments. Royalty acquisitions in 2022 totaled up to $3.5 billion, bolstering its growth outlook.
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two upcoming investor conferences. The events include the SVB Securities Global Biopharma Conference on February 16 at 10:40 a.m. ET and the Cowen 43rd Annual Health Care Conference on March 7 at 11:10 a.m. ET. The webcasts for these conferences will be available on Royalty Pharma’s Events page and will remain accessible for at least thirty days after the events. Royalty Pharma, founded in 1996, is a leader in biopharmaceutical royalty acquisition and funding innovation in the industry, boasting a portfolio exceeding 35 commercial products. For more details, visit their official website.
Royalty Pharma (RPRX) announced it will report its Q4 and full year 2022 financial results on February 15, 2023, before the U.S. markets open. The company will host a conference call at 8:00 a.m. ET to discuss the results. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation across the industry, supporting numerous therapies through its extensive portfolio of royalties from over 35 commercial products, such as Vertex’s Trikafta and Biogen’s Tysabri. For further details, visit their Investors page.
Royalty Pharma (RPRX) has reported a strong operational performance for 2022, forecasting Net cash provided by operating activities of approximately $2.14 billion to $2.15 billion and Adjusted Cash Receipts of $2.785 billion to $2.79 billion, marking a 31% year-over-year growth. The company has achieved significant capital deployment, announcing $10 billion in transactions since 2020, projected to contribute $1 billion to future receipts. Management emphasizes resilience amid revenue declines in key areas, positioning for innovation and growth.
Royalty Pharma (RPRX) announced its acquisition of an interest in SPINRAZA® and pelacarsen royalties from Ionis Pharmaceuticals. The deal totals up to $1.125 billion, including a $500 million upfront payment and up to $625 million in milestone payments. Ionis retains a majority of the royalties and milestone payments for pelacarsen, expected to advance its late-stage programs and innovative pipeline. This partnership aims to enhance the commercial readiness of Ionis’s therapies targeting spinal muscular atrophy and cardiovascular diseases.
Ionis Pharmaceuticals has announced a significant royalty agreement with Royalty Pharma, involving an upfront payment of $500 million and potential milestones of up to $625 million. This deal allows Royalty Pharma to acquire an interest in Ionis' royalties from SPINRAZA and pelacarsen, while Ionis retains the majority of royalties and milestone payments from Novartis. The investment aims to bolster Ionis' late-stage programs and innovative genetic medicines pipeline, highlighting confidence in the commercial potential of both therapies.
Royalty Pharma plc (Nasdaq: RPRX) has declared a quarterly dividend of $0.20 per Class A share for the first quarter of 2023, marking a 5.3% increase from the previous quarter. The dividend will be paid on March 15, 2023, to shareholders of record as of February 16, 2023. CEO Pablo Legorreta emphasized the company's commitment to returning capital to shareholders while maintaining financial flexibility for future innovations, noting strong demand for capital in the biopharma sector.
Royalty Pharma, listed on Nasdaq as RPRX, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The presentation can be accessed via the company's Events page and will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leader in biopharmaceutical royalties, funding innovation through collaborations with various biopharmaceutical entities. Its portfolio includes royalties from over 35 commercial products.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
